Search clinical trials for: R-DA-EPOCH-21

Total 58 results

Dana-Farber Cancer Institute
Genentech, Inc.

Recruiting

A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome

Richter Syndrome

United States
Elena N.Parovichnikova

Recruiting

R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)

Lymphoma, High-Grade

Russian Federation
Nordic Lymphoma Group
Helsinki University Central Hospital; Aarhus University Hospital

Recruiting

Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis (Bio-CHIC)

Lymphoma, Large B-Cell, Diffuse

Denmark, Norway, Sweden, Finland
Shandong Provincial Hospital

Recruiting

Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | B-cell NonHodgkin Lymphoma

China
Dong-A ST Co., Ltd.

Recruiting

Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients

Hepatitis B

Korea, Republic of
Dong-A ST Co., Ltd.

Completed

Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects (DA-2811)

Healthy

Korea, Republic of
National Research Center for Hematology, Russia
National Research Center for Hematology

Recruiting

R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis

Diffuse Large B-Cell Lymphoma

Russian Federation
Dong-A ST Co., Ltd.

Not yet recruiting

Phase III Clinical Trial of DA-5212 in Patients With Functional Dyspepsia

Functional Dyspepsia

Korea, Republic of
Dong-A ST Co., Ltd.

Recruiting

A Clinical Trial to Compare the Safety, Tolerability, and PK Properties of DA-5216 and DA-5216-R and to Evaluate the Food Effect on DA-5216.

Healthy

Korea, Republic of
Dong-A ST Co., Ltd.

Completed

Phamacokinetics and Safety Profiles of DA-5213 10mg in Healthy Subjects

Healthy

Korea, Republic of
Dong-A ST Co., Ltd.

Not yet recruiting

Bioequivalence Study Between "DA-5215 Tab" and "DA-5215-R Tab"

Healthy

Korea, Republic of
Stichting Hemato-Oncologie voor Volwassenen Nederland

Active, not recruiting

DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL (HO152)

Lymphoma, B-Cell | Non Hodgkin Lymphoma | High-grade B-cell Lymphoma | MYC Translocation | BCL-2 Translocation

Netherlands, Belgium
Dong-A ST Co., Ltd.

Completed

Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fasting State

Healthy

Korea, Republic of
Dong-A ST Co., Ltd.

Completed

Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fed State

Healthy

Korea, Republic of
Dong-A ST Co., Ltd.

Completed

Phamacokinetics and Safety Profiles of DA-5210 10/1000mg in Healthy Subjects at Fasting State

Healthy

Korea, Republic of
Fudan University

Terminated

Dose-adjusted EPOCH-R in MYC Positive DLBCL

Diffuse Large B-cell Lymphoma

China
Dong-A ST Co., Ltd.

Completed

Phamacokinetics and Safety Profiles of DA-5210 10/1000mg in Healthy Subjects at Fed State

Healthy

Korea, Republic of
Pharmacyclics LLC.
Celgene Corporation

Completed

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma Refractory | Diffuse Large B Cell Lymphoma Relapsed

United States
Shandong Provincial Hospital

Recruiting

Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

China
Institute of Hematology & Blood Diseases Hospital
Xian-Janssen Pharmaceutical Ltd.

Not yet recruiting

R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL (BDHRT001)

Richter Transformation

China
National Institute of Medical Sciences and Nutrition...

Completed

Impact in the Medical Care Among the Rheumatic Diseases Patients in a Hospital in México During COVID-19 Pandemic

Quality of Life | Rheumatoid Arthritis

Mexico
Fujian Medical University

Active, not recruiting

R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL

Diffuse Large B-cell Lymphoma

China
Dong-A Pharmaceutical Co., Ltd.

Completed

A Study to Evaluate the Tolerability, Safety and Pharmacokinetic Characteristics of DA-3803

Infertility | Induction of Ovulation
St. Luke's-Roosevelt Hospital Center
GlaxoSmithKline

Withdrawn

Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy

Atopic Dermatitis

United States
Baylor College of Medicine
National Cancer Institute (NCI)

Completed

Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (DA-EPOCH-R)

Diffuse Large B Cell Lymphoma | Post Transplant Lymphoproliferative Disorder | Primary Mediastinal (Thymic) Large B-cell Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | NHL | DLBCL

United States
National Cancer Institute (NCI)

Completed

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

Mantle Cell Lymphoma | Lymphoma, Mantle Cell

United States
National Cancer Institute (NCI)

Completed

Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

Burkitt Lymphoma | Plasmablastic Lymphoma | Diffuse Large B-cell Lymphoma, c-MYC Positive

United States
National Cancer Institute (NCI)

Terminated

Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders

Leukemia | Multiple Myeloma | MDS | Non-Hodgkins Lymphoma | Hodgkins Lymphoma

United States
Ontario Clinical Oncology Group (OCOG)
Hoffmann-La Roche

Completed

A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL (CATCH)

HIV Infections | Lymphoma, AIDS Related

Canada
Universidade Federal do Rio de Janeiro

Completed

Lopinavir/r Monotherapy as Maintenance Therapy After Long Term Viral Suppression

HIV Infections

Brazil
Washington University School of Medicine
National Cancer Institute (NCI)

Completed

Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography

Breast Cancer

United States
St. Jude Children's Research Hospital
Assisi Foundation; Cookies for Kids' Cancer

Completed

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood B-Lymphoblastic Lymphoma

United States
The First Affiliated Hospital with Nanjing Medical...

Unknown

Trial of DA-EPOCH Regimen for NHL With HLH

NHL With Hemophagocytic Lymphohistiocytosis

China
Yale University
Kyowa Kirin, Inc.

Not yet recruiting

Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma

T Cell Lymphoma

United States
French National Agency for Research on AIDS and...
University of Bergen; The Research Council of Norway; European and Developing... and other collaborators

Completed

Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding

HIV Infections

Burkina Faso, South Africa, Uganda, Zambia
Shanghai Public Health Clinical Center

Unknown

The Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma

To Evaluate the Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma
National Cancer Institute (NCI)

Completed

Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma

Mantle Cell Lymphoma | Lymphoma, Mantle Cell

United States
Tianjin Medical University Cancer Institute and...

Not yet recruiting

A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission

Radiotherapy | Advanced Diffuse Large B-Cell Lymphoma | Extra-nodal Involvement, Large Mass
National Center for Women and Children's Health...
National Center for AIDS/STD Control and Prevention, China CDC; Guangdong Provincial... and other collaborators

Completed

Antiretroviral Regime for Viral Eradication in Newborns

HIV/AIDS and Infections

China
Ronaldo de Matos Esmeraldo, MD
Novartis Pharmaceuticals

Completed

Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant

Cytomegalovirus Infections | Transplantation Infection

Brazil
Novartis Pharmaceuticals

Recruiting

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (LEDA)

Follicular Lymphoma (FL)

Australia, Spain, Singapore, Korea, Republic of, Poland, Taiwan, Hungary, Slovakia
ANRS, Emerging Infectious Diseases
University of Bordeaux; PACCI Program

Unknown

Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial (INTENSE-COV)

COVID-19 | Severe Acute Respiratory Syndrome Coronavirus 2 | COVID-19 Drug Treatment

Côte D'Ivoire
ANRS, Emerging Infectious Diseases

Completed

First-Line Treatment for HIV-2 (FIT-2)

HIV-2 Infection

Côte D'Ivoire, Burkina Faso, Senegal, Togo
International Maternal Pediatric Adolescent AIDS...
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

HIV Infections

United States, Puerto Rico
University of California, San Francisco

Completed

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut (PLUS)

HIV Infections

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

Hematopoietic and Lymphoid Cell Neoplasm | Sarcoma | Lymphoma | Breast Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Aplastic Anemia | de Novo Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States

Search clinical trials for: R-DA-EPOCH-21

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations